High yield NSAIDS related points i must know for usmle. Organize systemwise
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have enough information from the textbooks to compile a comprehensive, well-organized USMLE-focused NSAID review. Let me write the answer:
NSAIDs - High Yield USMLE Points (System-by-System)
MECHANISM OF ACTION
- NSAIDs inhibit cyclooxygenase (COX-1 and COX-2), blocking conversion of arachidonic acid to prostaglandins, thromboxane A2 (TxA2), and prostacyclin (PGI2).
- COX-1: constitutively expressed - maintains gastric mucosa (PGE2), platelet aggregation (TxA2), and renal perfusion.
- COX-2: inducible - mediates inflammation, fever, pain. Also expressed constitutively in kidney, CNS, vascular endothelium.
- Aspirin is the ONLY NSAID that irreversibly (covalent acetylation) inhibits COX-1 > COX-2. All other NSAIDs are reversible.
- Most NSAIDs are weak organic acids (exception: nabumetone is a ketone prodrug metabolized to active acid form).
COX Selectivity Ladder (most to least GI-safe):
Celecoxib > Meloxicam > Diclofenac > Ibuprofen > Naproxen > Aspirin (high dose) > IndomethacinGI SYSTEM
Most tested side effect of NSAIDs
| Fact | Detail |
|---|---|
| Mechanism | Inhibit PGE2/PGI2 → ↓ mucus + bicarbonate secretion + ↓ mucosal blood flow → peptic ulcer |
| Also | Topical irritation - NSAIDs are weak acids that penetrate epithelial cells → direct injury |
| Prevalence | Endoscopic ulcers in 15-30% of regular users; complicated by bleeding in ~1.5%/year |
| Dyspepsia | 50-60% of users; over 80% of serious GI complications have NO preceding dyspepsia |
| Even low-dose aspirin | 75-325 mg/day mucosal injury rate: 8-60%; no NSAID dose is completely safe |
| H. pylori synergy | H. pylori + NSAIDs are independent AND synergistic risk factors for PUD |
| Risk factors for GI bleed | Advanced age, prior ulcer, concurrent glucocorticoids, high-dose/multiple NSAIDs, anticoagulants, clopidogrel, SSRIs (reduce platelet serotonin) |
Prevention strategies:
- Add PPI (e.g., omeprazole) or misoprostol (PGE1 analog) with NSAIDs in high-risk patients
- Switch to celecoxib (selective COX-2 spares COX-1 mediated gastric protection)
- Diclofenac + misoprostol and diclofenac + omeprazole are available combination preparations
Diclofenac special note: Causes hepatotoxicity (elevated aminotransferases) more than other NSAIDs - check LFTs.
CARDIOVASCULAR SYSTEM
| Mechanism | Selective COX-2 inhibitors block vascular PGI2 (prostacyclin, vasodilatory/anti-aggregatory) WITHOUT blocking platelet TxA2 (COX-1 dependent) → net pro-thrombotic state → ↑ MI and stroke risk |
|---|---|
| Traditional NSAIDs | Also increase CV risk (except naproxen, which may be least pro-thrombotic) |
| Aspirin (low dose) | Anti-thrombotic: irreversibly inhibits COX-1 in platelets → ↓ TxA2 → ↓ platelet aggregation (cardioprotective) |
Key tested points:
- COX-2 inhibitors: increased risk of MI, stroke, heart failure, hypertension - especially rofecoxib (Vioxx, withdrawn 2004)
- Current recommendation: use COX-2 inhibitors only when necessary and at lowest dose
- NSAIDs cause sodium and water retention (↓ renal prostaglandins → ↓ natriuresis) → worsen hypertension and heart failure
- NSAIDs blunt the effect of antihypertensives (especially ACE inhibitors, ARBs, diuretics, beta-blockers)
- Naproxen appears to have the most favorable CV safety profile among NSAIDs
RENAL SYSTEM
| Mechanism | Renal prostaglandins (PGE2, PGI2) are vasodilatory; normally NOT critical in healthy patients, but essential in states of reduced renal perfusion |
|---|---|
| Who is at risk | Hypovolemia, CHF, cirrhosis, diabetic nephropathy, pre-existing CKD - in these states NSAIDs can precipitate AKI |
| Electrolytes | ↓ Renin secretion → ↓ aldosterone → hyperkalemia; sodium/water retention |
| COX-2 in kidney | Constitutively expressed in kidney - so COX-2 inhibitors also cause nephrotoxicity |
| Contraindication | NSAIDs are contraindicated in cirrhosis with ascites (patients depend on renal PG vasodilation to maintain GFR) |
Classic USMLE trap: A patient with CHF or cirrhosis given NSAIDs → develops AKI + hyperkalemia. Note that normal healthy kidneys are NOT dependent on prostaglandins, so AKI from NSAIDs does NOT develop in patients with normal kidney function at baseline.
HEMATOLOGIC SYSTEM
| Drug | Platelet Effect | Duration |
|---|---|---|
| Aspirin | Irreversibly inhibits COX-1 → ↓ TxA2 → ↓ platelet aggregation + ↑ bleeding time | Lasts 7-10 days (platelet lifespan) |
| Other NSAIDs | Reversible inhibition of COX-1 → transient ↓ platelet aggregation | Returns to normal when drug cleared |
| Celecoxib | Minimal platelet effect (spares COX-1) | - |
Key points:
- Aspirin prolongs bleeding time but does NOT affect PT/PTT/INR
- NSAIDs + anticoagulants = high risk of serious GI bleeding - synergistic effect
- SSRIs + NSAIDs: ↑ GI bleeding (SSRIs ↓ platelet serotonin stores → ↓ platelet aggregation)
- In surgical patients: stop regular NSAIDs ~3-5 half-lives before surgery; hold aspirin 7-10 days pre-op (unless on antiplatelet therapy for cardiovascular indication)
RESPIRATORY SYSTEM
Aspirin-Exacerbated Respiratory Disease (AERD) / Samter's Triad:
| Feature | Detail |
|---|---|
| Triad | Asthma + Nasal polyps + Aspirin/NSAID sensitivity |
| Pathophysiology | COX-1 inhibition diverts arachidonic acid to lipoxygenase pathway → ↑ leukotrienes (LTC4, LTD4, LTE4) → bronchoconstriction |
| Prevalence | 10% of asthmatics; common in adults |
| Trigger | All COX-1 inhibitors (aspirin, most NSAIDs) |
| Safe alternatives | Celecoxib (selective COX-2), acetaminophen (low doses), opioids |
Note: Traditional NSAIDs and high-dose aspirin can worsen asthma even without the full Samter's triad.
CNS / FEVER
- NSAIDs are antipyretic: inhibit COX-2-derived PGE2 in the hypothalamus → reset the thermostat
- Also analgesic (peripheral + central COX inhibition)
- Aspirin in children with viral illness → Reye's syndrome (hepatic encephalopathy + fatty liver + hyperammonemia) - this is why aspirin is contraindicated <18 years with viral illness
- Indomethacin: strongest CNS penetration among NSAIDs → most likely to cause headache, dizziness, cognitive effects; also used IV/PO to close patent ductus arteriosus (PDA) in neonates
PREGNANCY / OBSTETRICS
| Trimester | Effect |
|---|---|
| First trimester | Avoid - NSAIDs may interfere with implantation |
| Before 20 weeks | Low-dose aspirin is used to prevent preeclampsia (per ACOG) |
| After 20 weeks | NSAIDs → premature closure of ductus arteriosus (via ↓ PGE2/PGI2) - contraindicated |
| Labor | NSAIDs delay labor, reduce uterine contractility (prostaglandins needed for cervical ripening and labor) |
| Indomethacin | Used as tocolytic (short-term) to delay preterm labor; risk of fetal PDA closure limits use after 32 weeks |
| Aspirin at delivery | Avoid; increases maternal and neonatal bleeding |
SPECIAL DRUG-SPECIFIC POINTS
| Drug | Key USMLE Fact |
|---|---|
| Aspirin (high dose) | Tinnitus and hearing loss (salicylism); at toxic levels: respiratory alkalosis then metabolic acidosis (stimulates medullary respiratory center → then uncouples oxidative phosphorylation) |
| Aspirin (low dose) | Antiplatelet; prevents MI, stroke, colon cancer recurrence |
| Celecoxib | Selective COX-2; GI-sparing, but ↑ CV risk; safe in aspirin-allergy/AERD |
| Indomethacin | PDA closure; tocolytic; most potent NSAID; highest CNS toxicity; also used in acute gout and ankylosing spondylitis |
| Ketorolac | Potent IV/IM NSAID; post-op pain; maximum 5 days use (renal toxicity risk) |
| Ibuprofen | OTC; if given with aspirin, can block aspirin's antiplatelet effect (competitive COX-1 inhibition - ibuprofen given before aspirin prevents aspirin's irreversible binding) |
| Naproxen | Long half-life (12-17h); most favorable CV profile among non-selective NSAIDs |
| Diclofenac | Liver enzyme elevation (most hepatotoxic NSAID); topical formulation available |
| Meloxicam | Preferential COX-2 selectivity at low doses (7.5mg); fewer GI symptoms |
DRUG INTERACTIONS (High Yield)
| Interaction | Mechanism / Consequence |
|---|---|
| NSAIDs + Warfarin | Displacement from albumin + GI mucosal injury → ↑ bleeding risk |
| NSAIDs + Lithium | ↓ Renal lithium excretion → lithium toxicity |
| NSAIDs + Methotrexate | ↓ Renal MTX excretion → MTX toxicity |
| NSAIDs + ACE inhibitors/ARBs | Blunt antihypertensive effect; risk of AKI ("triple whammy" with diuretic) |
| NSAIDs + Diuretics | Blunt natriuretic effect; edema, worsened CHF |
| Ibuprofen + Aspirin | Ibuprofen competitively blocks COX-1 → aspirin cannot acetylate → loses cardioprotective effect |
| Celecoxib + Sulfonamide allergy | Celecoxib is a sulfonamide derivative → potential cross-reaction |
| Diclofenac + Voriconazole | Voriconazole inhibits CYP2C9 → ↑ diclofenac levels/toxicity |
QUICK SUMMARY TABLE
| Organ | Classic NSAID Effect | Key Drug |
|---|---|---|
| GI | Peptic ulceration, GI bleed | All NSAIDs (Aspirin worst) |
| CV | ↑ MI/stroke, HTN, fluid retention | Celecoxib / Rofecoxib |
| Renal | AKI (in compromised patients), hyperkalemia | All NSAIDs |
| Platelet | Irreversible inhibition | Aspirin only |
| Respiratory | Bronchoconstriction (AERD) | Aspirin, NSAIDs |
| Fetus | Premature ductus closure | After 20 weeks |
| Liver | Elevated LFTs | Diclofenac |
| CNS | Reye's syndrome | Aspirin + viral infection |
| Obstetrics | Tocolysis | Indomethacin |
| PDA closure | Inhibit PGE2-mediated patency | Indomethacin |
Sources: Katzung's Basic and Clinical Pharmacology 16e, Ch. 35-36; Harrison's Principles of Internal Medicine 22e, Ch. 335; Goodman & Gilman's Pharmacological Basis of Therapeutics; Robbins & Cotran Pathologic Basis of Disease; Sleisenger & Fordtran's GI and Liver Disease.
This is a shared conversation. Sign in to Orris to start your own chat.